| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629959 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9533102 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9180259 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8562564 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US11446441 | COVIS | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US8021335 | COVIS | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US11446440 | COVIS | Needle assisted injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US9789257 | COVIS | Needle assisted injection device having reduced trigger force |
Feb, 2034
(10 years from now) | |
| US11154562 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US9844558 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US10471075 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US11304962 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
Makena is owned by Covis.
Makena contains Hydroxyprogesterone Caproate.
Makena has a total of 12 drug patents out of which 0 drug patents have expired.
Makena was authorised for market use on 03 February, 2011.
Makena is available in solution;intramuscular, solution;subcutaneous dosage forms.
Makena can be used as reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
The generics of Makena are possible to be released after 02 May, 2036.
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 03 February, 2011
Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS
MAKENA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic